Figure 1.
Figure 1. Generation of genetically modified EBV-specific cytotoxic T lymphocytes (CTLs). Peripheral blood mononuclear cells were used to generate both EBV-LCLs and EBV-specific CTLs. The CTLs were then transduced with an SFG retrovirus containing the human CD40L promoter driving the adenovirus E1 gene. These E1-transduced cells (C-RE) are then transduced with an Ad5F35 adenovector. Following activation by autologous EBV-LCLs, these CTLs (C-RE-AG) are activated and release infectious adenovectors. LTR indicates long terminal repeat.

Generation of genetically modified EBV-specific cytotoxic T lymphocytes (CTLs). Peripheral blood mononuclear cells were used to generate both EBV-LCLs and EBV-specific CTLs. The CTLs were then transduced with an SFG retrovirus containing the human CD40L promoter driving the adenovirus E1 gene. These E1-transduced cells (C-RE) are then transduced with an Ad5F35 adenovector. Following activation by autologous EBV-LCLs, these CTLs (C-RE-AG) are activated and release infectious adenovectors. LTR indicates long terminal repeat.

Close Modal

or Create an Account

Close Modal
Close Modal